SCHEMBL455908

SCHEMBL455908

O=C1C(=NNC(=S)Nc2ccc([N+](=O)[O-])cc2)Nc2ccc(Br)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RRM1 P23921 1/20 0.44
RRM2 P31350 1/20 0.44
RRM2B Q7LG56 1/20 0.44
HSPA9 P38646 2/20 0.43
ALDH1A1 P00352 7/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
CAPN9 O14815 1/20 0.40
CASP3 P42574 1/20 0.40
MAPT P10636 6/20 0.40
LMNA P02545 4/20 0.40
CYP19A1 P11511 1/20 0.39
HTT P42858 3/20 0.39
GAA P10253 2/20 0.39
ALOX12 P18054 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPC1 O15118 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
CA12 O43570 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13008061 0.86 CA12 (0.46) RRM1RRM2RRM2BHSPA9ALDH1A1
SCHEMBL457126 0.85 ALDH1A1 (0.51) HSPA9ALDH1A1SMN1; SMN2CAPN9CASP3
SCHEMBL455700 0.85 ALDH1A1 (0.47) RRM1RRM2RRM2BHSPA9ALDH1A1
SCHEMBL457072 0.85 MAPT (0.47) ALDH1A1SMN1; SMN2MAPTLMNAHTT
SCHEMBL457611 0.83 ALDH1A1 (0.47) HSPA9ALDH1A1SMN1; SMN2CAPN9CASP3
SCHEMBL469858 0.77 CA1 (0.54) RRM1RRM2RRM2BHSPA9ALDH1A1
SCHEMBL454941 0.76 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTLMNAGAA
SCHEMBL456020 0.76 LMNA (0.51) ALDH1A1SMN1; SMN2CAPN9CASP3MAPT
SCHEMBL31492083 0.75 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2MAPTHTTALOX12
SCHEMBL469859 0.74 CA1 (0.50) ALDH1A1MAPTCA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed